---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-002569"
form_type: "8-K"
ticker: "CRVS"
cik: "0001626971"
company_name: "Corvus Pharmaceuticals, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:07:48.148865+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Corvus Q1 net loss $5.7M; soquelitinib PTCL ORR 39%; $30.6M financing

## Summary
- Net loss $5.7M in Q1 2024 vs $7.9M in Q1 2023; R&D expense $4.1M.
- Cash $22.1M at March 31, 2024; plus $30.6M from May 6 financing; projected cash into Q4 2025.
- Soquelitinib Phase 1/1b PTCL: 39% ORR (5 CRs, 4 PRs) in 23 evaluable patients; disease control 61%.
- Phase 3 registrational trial for soquelitinib in PTCL planned to start Q3 2024.
- Ciforadenant Phase 1b/2 in RCC met predefined efficacy threshold; enrollment continues.

## SEC filing metadata
- accession: 0001171843-24-002569
- form_type: 8-K
- ticker: CRVS
- cik: 0001626971
- company_name: Corvus Pharmaceuticals, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1626971/000117184324002569/0001171843-24-002569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1626971/000117184324002569/f8k_050624.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-002569
- JSON: https://secwatch.observer/filing/0001171843-24-002569.json
- Plain text: https://secwatch.observer/filing/0001171843-24-002569.txt

## Key facts
- Earnings Releases
  Corvus Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2024.
  - Period: the first quarter ended March 31, 2024
  - Result: reported results
  source text: Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1626971/000117184324002569/0001171843-24-002569-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.